Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice
- PMID: 35500802
- DOI: 10.1016/j.jep.2022.115333
Penthorum chinense Pursh. extract attenuates non-alcholic fatty liver disease by regulating gut microbiota and bile acid metabolism in mice
Abstract
Ethnopharmacological relevance: Penthorum chinense Pursh. (PCP) is commonly used as a Miao ethnomedicine and health food for liver protection in China. Gansukeli (WS3-B-2526-97) is made from the extract of PCP (PCPE) for the treatment of viral hepatitis. In recent years, PCPE has been reported in the treatment of non-alcoholic fatty liver disease (NAFLD), however its potential mechanism is not fully elucidated.
Aim of the study: To investigate the ameliorating effect of PCPE on high-fat diet (HFD)-induced NAFLD mice and demonstrate whether its protective effect is gut microbiota dependent and associated with bile acid (BA) metabolism.
Materials and methods: The alleviating effect of PCPE on NAFLD was conducted on male C57BL/6J mice fed an HFD for 16 weeks, and this effect associated with gut microbiota dependent was demonstrated by pseudo-germfree mice treated with antibiotics and fecal microbiota transplantation (FMT). The composition of the gut microbiota in the cecum contents was analyzed by 16S rRNA sequencing, and the levels of BAs in liver and fecal samples were determined by UPLC/MS-MS.
Results: The results showed that administration of PCPE for 8 weeks could potently ameliorate HFD-induced NAFLD and alleviate dyslipidemia and insulin resistance. Moreover, PCPE treatment alleviated gut dysbiosis, especially reducing the relative abundance of bile salt hydrolase (BSH)-producing bacteria. Furthermore, PCPE significantly increased the levels of taurine-conjugated BAs in feces, such as tauro-β-muricholic acid (T-βMCA), tauroursodesoxycholic acid (TUDCA), and taurochenodeoxycholic acid (TCDCA), and increased hepatic chenodeoxycholic acid (CDCA). The protein and mRNA expression of farnesoid X receptor (FXR) and fibroblast growth factor 15 (FGF15) were decreased in intestine, increased taurine-conjugated BAs inhibited the intestinal signaling pathway, which was associated with increased genes expression of enzymes in the alternative BA synthesis pathway that reduced the levels of cholesterol. The increased CDCA produced via the alternative BA synthesis pathway promoted hepatic FXR activation and BA excretion.
Conclusion: Our study is the first time to demonstrate that PCPE could ameliorate NAFLD in HFD-induced mice by regulating the gut microbiota and BA metabolism, and from a novel perspective, to clarify the mechanism of PCPE in NAFLD.
Keywords: Bile acid; Farnesoid X receptor; Fecal microbiota transplantation; Gut microbiota; Non-alcoholic fatty liver disease; Penthorum chinense Pursh..
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Sanye tablet regulates gut microbiota and bile acid metabolism to attenuate hepatic steatosis.J Ethnopharmacol. 2025 Apr 9;345:119514. doi: 10.1016/j.jep.2025.119514. Epub 2025 Feb 17. J Ethnopharmacol. 2025. PMID: 39971018
-
Ileal Bile Acid Transporter Inhibitor Improves Hepatic Steatosis by Ameliorating Gut Microbiota Dysbiosis in NAFLD Model Mice.mBio. 2021 Aug 31;12(4):e0115521. doi: 10.1128/mBio.01155-21. Epub 2021 Jul 6. mBio. 2021. PMID: 34225483 Free PMC article.
-
Nuciferine Protects Against High-Fat Diet-Induced Hepatic Steatosis via Modulation of Gut Microbiota and Bile Acid Metabolism in Rats.J Agric Food Chem. 2022 Sep 28;70(38):12014-12028. doi: 10.1021/acs.jafc.2c04817. Epub 2022 Sep 15. J Agric Food Chem. 2022. PMID: 36106619
-
An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.Gastroenterology. 2016 Nov;151(5):845-859. doi: 10.1053/j.gastro.2016.08.057. Epub 2016 Sep 14. Gastroenterology. 2016. PMID: 27639801 Free PMC article. Review.
-
Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.J Cell Biochem. 2019 Mar;120(3):2713-2720. doi: 10.1002/jcb.27635. Epub 2018 Nov 15. J Cell Biochem. 2019. PMID: 30443932 Review.
Cited by
-
Zhi-Kang-Yin formula attenuates high-fat diet-induced metabolic disorders through modulating gut microbiota-bile acids axis in mice.Chin Med. 2024 Oct 18;19(1):145. doi: 10.1186/s13020-024-01021-w. Chin Med. 2024. PMID: 39425211 Free PMC article.
-
Shenling Baizhu San ameliorates non-alcoholic fatty liver disease in mice by modulating gut microbiota and metabolites.Front Pharmacol. 2024 Apr 24;15:1343755. doi: 10.3389/fphar.2024.1343755. eCollection 2024. Front Pharmacol. 2024. PMID: 38720776 Free PMC article.
-
Penthorum chinense Pursh improves type 2 diabetes mellitus via modulating gut microbiota in db/db mice.BMC Complement Med Ther. 2023 Sep 9;23(1):314. doi: 10.1186/s12906-023-04136-z. BMC Complement Med Ther. 2023. PMID: 37689643 Free PMC article.
-
Integration bile acid metabolomics and gut microbiome to study the anti-liver fibrosis effects of total alkaloids of Corydalis saxicola Bunting.Chin Med. 2025 Jul 4;20(1):106. doi: 10.1186/s13020-025-01158-2. Chin Med. 2025. PMID: 40611207 Free PMC article.
-
Ameliorative effects of Penthorum chinense Pursh on insulin resistance and oxidative stress in diabetic obesity db/db mice.PLoS One. 2024 Oct 7;19(10):e0311502. doi: 10.1371/journal.pone.0311502. eCollection 2024. PLoS One. 2024. PMID: 39374222 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials